CELLECTAR BIOSCIENCES INC (CLRB)
US15117F8077 - Common Stock
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains.
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private.
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
CLRB stock results show that Cellectar Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Management to host a conference call today at 8:30 am ET
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...
Cellectar Biosciences to Present at the 36th Annual Roth Conference
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that iopofosine I 131 in combination with external beam radiation therapy (EBRT) was safe and tolerated in a SPORE Grant supported investigator-initiated Phase 1 clinical trial.
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health’s National Cancer Institute (NCI)...
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
Cellectar stock climbs 8% on results for CNS malignancy therapy (NASDAQ:CLRB)
Cellectar (CLRB) stock jumped 8% after it reported positive results from a study of its phospholipid radiotherapeutic conjugate in the treatment of Waldenstrom’s macroglobulinemia.
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development...
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human...
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
Dr. Levy to Provide Perspective on Iopofosine I 131’s Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia...
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy...
Wells Fargo Is Warming Up to Enphase Energy (ENPH) Stock
Enphase Energy stock is rising higher on Monday as investors react to a new upgrade and increased price target for ENPH from Wells Fargo.
Why Is Spirit AeroSystems (SPR) Stock Down 14% Today?
Spirit AeroSystems stock is falling hard on Monday as investors in SPR react to one of the company's flights experiencing a mid-air blowout.
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday!
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Cellectar Biosciences stock is up on Monday as investors celebrate positive study results with heavy trading of CLRB stock this morning.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!
Cellectar Biosciences stock jumps on radiotherapy data
Cellectar Biosciences (CLRB) stock rises in reaction to positive topline data from the company's pivotal trial for radiotherapy iopofosine I 131. Read more here.
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Iopofosine tested in heavily pretreated multi-class refractory population with a median of four prior therapies and achieves 75.6% Overall Response Rate;...
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments...
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads...
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
Presentation to Discuss Advancing Universal Targeted Radiotherapies...
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time...
Cellectar Biosciences files to sell 34.5M shares for holders (NASDAQ:CLRB)
Cellectar Biosciences (CLRB) plans to offer and sell up to 34.5 million shares in a secondary offering, according to an SEC filing.
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without...
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...
Cellectar Biosciences announces up to ~$103M private placement financing (NASDAQ:CLRB)
Cellectar Biosciences (CLRB), a late-stage clinical biopharmaceutical company, Tuesday said it has entered into a securities purchase agreement with certain institutional investors for...